Christine J. Guico-Pabia, MD, MBA, MPH
- 9Articles
- 31.6KReads
- 2009–2015Active
- 25Collaborators
- 317Citations
About
Christine J. Guico-Pabia, MD, MBA, MPH, has authored multiple publications between 2009 and 2015 focusing on major depressive disorder (MDD) and its treatment. Her work includes analyses of desvenlafaxine’s efficacy, relapse rates, and adverse events in depression, as well as studies on cytochrome P450 2D6 phenoconversion and its impact on antidepressant response. She has also contributed to research on improving depression care quality and real-world patient outcomes.
Publications
A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d
June 4, 2015
An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder
February 26, 2015
Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder
February 5, 2015
Improving Quality of Depression Care Using Organized Systems of Care: A Review of the Literature
February 10, 2011
Beyond Symptomatic Improvement: Assessing Real-World Outcomes in Patients With Major Depressive Disorder
April 15, 2010
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
